Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; VET3 TGI (Primary) ; VET3 TGI (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Cervical cancer; Colorectal cancer; Head and neck cancer; Male breast cancer; Oesophageal cancer; Ovarian cancer; Renal cancer; Sarcoma; Solid tumours; Thymoma; Uterine cancer
  • Focus Adverse reactions
  • Acronyms STEALTH-001
  • Sponsors KaliVir Immunotherapeutics

    • Most Recent Events

    • 08 Oct 2024 According to KaliVir Immunotherapeutics media release, first patient has been dosed in this study.
    • 20 Sep 2024 Status changed from not yet recruiting to recruiting.
    • 01 Jul 2024 According to KaliVir Immunotherapeutics media release, the FDA has cleared the Investigational New Drug (IND) application for the STEALTH-001 study of VET3-TGI in patients with incurable, advanced solid tumors.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top